{"product_id":"cjc-1295","title":"CJC-1295 with DAC","description":"\u003ch4 style=\"text-align: left;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: #00e2ff;\"\u003eCJV-1295 with DAC\u003c\/span\u003e\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cdiv class=\"n6owBd awi2gc\" style=\"text-align: left;\"\u003e\n\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003e\u003cspan style=\"color: rgb(128, 128, 128);\"\u003eCJC-1295 with DAC is a synthetic, long-acting analogue of growth hormone-releasing hormone (GHRH), designed to interact with GHRH receptors and influence growth-hormone signalling pathways. It is commonly investigated within peptide pharmacology and endocrine research.\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"color: rgb(128, 128, 128);\"\u003eThe DAC (Drug Affinity Complex) modification is designed to extend the peptide's stability and activity by promoting reversible binding to albumin in circulation. This gives CJC-1295 with DAC a substantially longer activity profile than shorter-acting GHRH peptide analogues.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"color: rgb(128, 128, 128);\"\u003eIn laboratory research, CJC-1295 with DAC is studied to investigate GHRH receptor signalling, growth-hormone secretion, peptide stability and pharmacokinetics. Experimental models may also examine downstream markers associated with the GH\/IGF-1 signalling pathway.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"color: rgb(128, 128, 128);\"\u003eIt is primarily of interest in preclinical, biochemical and peptide research, particularly where researchers require a longer-acting GHRH analogue for controlled experimental models. Research use only.\u003c\/span\u003e\u003c\/p\u003e\n\u003cbr\u003e\u003c!--TgQPHd|[]--\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"n6owBd awi2gc\" style=\"text-align: left;\"\u003e\n\u003ch4 id=\"laboratory-research-data-analysis\"\u003e\u003cspan style=\"color: rgb(0, 226, 255);\"\u003e\u003cspan class=\"gs_tkn\"\u003eLaboratory \u003c\/span\u003e\u003cspan class=\"gs_tkn\"\u003eResearch \u003c\/span\u003e\u003cspan class=\"gs_tkn\"\u003eData \u003c\/span\u003e\u003cspan class=\"gs_tkn\"\u003eAnalysis\u003c\/span\u003e\u003c\/span\u003e\u003c\/h4\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"\"\u003e\n\u003cul style=\"margin-top: 0cm;\" type=\"disc\"\u003e\n\u003cli style=\"text-align: left; font-style: italic;\"\u003e\n\u003cstrong\u003ePeptide identity:\u003c\/strong\u003e LC-MS \/ mass spectrometry\u003c\/li\u003e\n\u003cli style=\"text-align: left; font-style: italic;\"\u003e\n\u003cstrong\u003ePurity assessment:\u003c\/strong\u003e HPLC analysis\u003c\/li\u003e\n\u003cli style=\"text-align: left; font-style: italic;\"\u003e\n\u003cstrong\u003eReceptor studies:\u003c\/strong\u003e investigation of GHRH receptor interaction\u003c\/li\u003e\n\u003cli style=\"text-align: left; font-style: italic;\"\u003e\n\u003cstrong\u003eGH pathway analysis:\u003c\/strong\u003e measurement of growth-hormone-related signalling markers\u003c\/li\u003e\n\u003cli style=\"text-align: left; font-style: italic;\"\u003e\n\u003cstrong\u003eIGF-1 pathway research:\u003c\/strong\u003e evaluation of downstream signalling responses\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp style=\"text-align: left; font-style: italic;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1040\/2005\/0265\/files\/CJC1295_with_DAC.png?v=1787862225\" alt=\"\"\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Bionik Peptides","offers":[{"title":"5mg","offer_id":59187553698137,"sku":"BP-5072-CJC-BIO-5MG","price":38.0,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1040\/2005\/0265\/files\/CJC-1295withDAC.png?v=1787872748","url":"https:\/\/bionikpeptides.com\/products\/cjc-1295","provider":"Bionik Peptides","version":"1.0","type":"link"}